Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Withdrawn 1Recruiting 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 1Dermatologic 1

Conditions

Melanoma 104Carcinoma, Renal Cell 38Leukemia, Myeloid, Acute 36Neoplasm Metastasis 31Neoplasms 22Breast Neoplasms 22Lymphoma, Non-Hodgkin 21Kidney Neoplasms 20Leukemia 18Carcinoma, Non-Small-Cell Lung 18Skin Neoplasms 17Neuroblastoma 17Ovarian Neoplasms 16Colorectal Neoplasms 15Recurrence 14Leukemia, Lymphocytic, Chronic, B-Cell 14Lymphoma 13Myelodysplastic Syndromes 10Uveal Melanoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, Follicular 9Head and Neck Neoplasms 9Uterine Cervical Neoplasms 8Multiple Myeloma 8Congenital Abnormalities 8Triple Negative Breast Neoplasms 7Stomach Neoplasms 7Lung Neoplasms 7Hodgkin Disease 7Squamous Cell Carcinoma of Head and Neck 6

Interventions

Temozolomide 162Radiosurgery 115Radiotherapy 100Bevacizumab 96Magnetic Resonance Spectroscopy 65Carboplatin 48Etoposide 34pembrolizumab 33Surgical Procedures, Operative 33Irinotecan 33Nivolumab 32Cyclophosphamide 32Erlotinib Hydrochloride 31Radiation 30Carmustine 28Lomustine 25Cisplatin 25Trastuzumab 23Ipilimumab 23Filgrastim 23Vincristine 20Mental Status and Dementia Tests 20Aminolevulinic Acid 19Topotecan 18Pemetrexed 18Capecitabine 18Specimen Handling 17Sorafenib 15Radiotherapy, Intensity-Modulated 15Imatinib Mesylate 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Brain Neoplasms × Interleukin-2 × Clear all
NCT06640582 2024-11-05

BAH2472

Essen Biotech

Phase 1/2 Recruiting
85 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Meningioma

NCT03297463 2018-08-01

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

Masonic Cancer Center, University of Minnesota

Phase 1/2 Withdrawn
CNSDermatologic

Brain Neoplasms, Melanoma

NCT01082926 2015-06-08

Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2

City of Hope Medical Center

Phase 1 Completed
6 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Meningioma, Oligodendroglioma, Neuroectodermal Tumors, Primitive, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡